grapiprant
Small moleculeexperimental
Grapiprant, sold under the brand name Galliprant, is a small molecule drug that belongs in the piprant class. This analgesic and anti-inflammatory drug is primarily used as a pain relief for mild to moderate inflammation related to osteoarthritis in dogs. Grapiprant has been approved by the FDA's Center for Veterinary Medicine and was categorized as a non-cyclooxygenase inhibiting non-steroidal anti-inflammatory drug (NSAID) in March 2016. — Wikipedia
Clinical trial activity
5 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2006 (NCT00392080)
Timeline
Indications
Mechanism of action
- Prostanoid EP4 receptorANTAGONIST
Prostanoid EP4 receptor antagonist
- Prostanoid EP4 receptorINHIBITOR
PTGER4 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCc1nc2c(C)nc(C)cc2n1-c1ccc(CCNC(=O)NS(=O)(=O)c2ccc(C)cc2)cc1- Mol. weight
- 491.62 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3039498 ↗
- WikipediaGrapiprant ↗
Also known as
- arys-007
- cj-023423
- cj-023423
- cj-023423
- cj-023,423
- grapiprant
- grapiprant
- grapiprant and pembrolizumab
- n-(((2-(4-(2-ethyl-4,6-dimethyl-1h-imidazo(4,5-c)pyridin-1-yl) phenyl)ethyl)amino)carbonyl)-4-methylbenzenesulfonamide
- rq-00000007
- rq-00000007
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05041101 | Phase 1/Phase 2 (Phase 2) | Nov 4, 2021 | University of Texas at Houston |
| NCT03696212 | Phase 1/Phase 2 (Phase 2) | Jan 8, 2019 | Arrys Therapeutics, Merck |
| NCT03658772 | Phase 1 | Sep 20, 2018 | Arrys Therapeutics, Merck |
| NCT02538432 | Phase 2 | Jun 1, 2017 | University of Maryland |
| NCT00392080 | Phase 1 | Nov 1, 2006 | Pfizer |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Arrys Therapeutics | For profit | 2 | 2 | 2 | 2018 |
| Merck | For profit | 2 | 0 | 2 | 2018 |
| Pfizer | For profit | 1 | 1 | 1 | 2006 |
| University of Maryland | Academic/Hospital | 1 | 1 | 1 | 2017 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2021 |
5 organizations
Page 1 / 1